Choosing estimands in clinical trials with missing data

Pharmaceutical Statistics

Volumn 16, Issue 1, 2017, Pages 29-36

  Mallinckrodt, Craig ^a   Molenberghs, Geert ^b,c   Rathmann, Suchitrita ^a  

^a ELI LILLY AND COMPANY   (United States)

^b HASSELT UNIVERSITY   (Belgium)

^c KU LEUVEN   (Belgium)

Author keywords

clinical trials; estimands; missing data

Indexed keywords

PLACEBO;

CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG EFFICACY; ESTIMAND; MEDICATION COMPLIANCE; PROTOCOL COMPLIANCE; SAMPLE SIZE; SENSITIVITY ANALYSIS; STATISTICAL CONCEPTS; STUDY DESIGN; HUMAN; METHODOLOGY; PROCEDURES; STANDARDS; STATISTICAL ANALYSIS; STATISTICAL MODEL;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84989316741     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1765     Document Type: Conference Paper

References (32)

1. Mallinckrodt CH. Preventing and treating missing data in longitudinal clinical trials: a practical guide. Cambridge University Press: New York, 2013.
2. Committee for Medicinal Products for Human Use (CHMP). Guideline on missing data in confirmatory clinical trials. 2010. EMA/CPMP/EWP/1776/99 Rev. 1.
3. National Research Council. The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Committee on National Statistics, Division of Behavioural and Social Sciences and Education. The National Academies Press: Washington, DC, 2010.
4. O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clinical Pharmacology and Therapeutics 2012; 91(3):550–554.
5. Molenberghs G, Kenward MG. Missing data in clinical studies. John Wiley & Sons: Chichester, 2007.
6. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal. 2008; 42:305–319.
7. Molenberghs G, Fitzmaurice G, Kenward M, Tsiatis A, Verbeke G. Handbook of missing data methodology. CRC Press: Boca Raton, 2015.
8. O'Kelly M, Ratitch B. Clinical trials with missing data. Wiley: Chichester, 2014.
9. Mallinckrodt CH, Kenward MG. Conceptual considerations regarding choice of endpoints, hypotheses, and analyses in longitudinal clinical trials. Drug Information Journal. 2009; 43(4):449–458.
10. Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structured approach to choosing estimands and estimators in longitudinal clinical trials. Pharmaceutical Statistics. 2012; 11:456–461.
11. Leuchs AK, Zinserling J, Brandt A, Wirtz D, Benda N. Choosing appropriate estimands in clinical trials. Therapeutic Innovation and Regulatory Science. 2015; 49:584–592.
12. Garrett A. Choosing appropriate estimands in clinical trials (Leuchs et al.): Letter to the editor. Therapeutic Innovation & Regulatory Science. 2015; 49:601.
13. Carpenter J, Roger J, Kenward M. Analysis of longitudinal trials with missing data: a framework for relevant, accessible assumptions, and inference via multiple imputation. Journal of Biopharmaceutical Statistics. 2013; 23:1352–1371.
14. Mallinckrodt CH, Roger J, Chuang-Stein C, et al. Recent developments in the prevention and treatment of missing data. Therapeutic Innovation and Regulatory Science. 2014; 48(1):68–80.
15. Mallinckrodt CH, Roger J, Chuang-Stein C, et al. Missing data: turning guidance into action. Statistics in Biopharmaceutical Research. 2013; 5(4):369–382.
16. Permutt T. A taxonomy of estimands for regulatory clinical trials with discontinuations. Statistics in Medicine. 2015a, DOI: 10.1002/sim.6841.
17. Phillips A, Abellan-Andres J, Andersen S, et al. Estimands: discussion points from the PSI estimands and sensitivity expert group. Pharm. Stat. 2017; 16:6 10.1002/pst.1745.
18. ICH guidelines. Available at: http://www.ich.org/fileadmin/Public/Web/Site/ICH/Products/Guidelines/Efficacy/E9/Step4/E9/Guideline.pdf (accessed 19.10.2015).
19. Buncher C, Ralph and Jia-Yeong Tsay. Statistics in the pharmaceutical industry (3rd edition). Chapman Hall/CRC Press: Boca Raton, FL USA, 2005.
20. Holubkov R1, Dean JM, Berger J, Anand KJ, Carcillo J, Meert K, Zimmerman J, Newth C, Harrison R, Willson DF, Nicholson C. Is “rescue” therapy ethical in randomized controlled trials? Pediatric Critical Care Medicine. 2009; 10(4):431–8.
21. Henning Z. Paracetamol and the placebo effect in osteoarthritis trials: a missing link? Pain Research and Treatment. 2011; 2011:6. Article ID 696791.
22. ICH guidelines. Available at: http://www.ich.org/fileadmin/Public/Web/Site/ICH/Products/Guidelines/Efficacy/E10/Step4/E10/Guideline.pdf (accessed 21.10.2015).
23. Verbeke G, Molenberghs G. Linear Mixed models for longitudinal data. Springer: New York, NY, USA, 2000.
24. Molenberghs G, Beunckens C, Sotto C, Kenward M. G. Every missing not at random model has got a missing at random counterpart with equal fit. Journal of the Royal Statistical Society, Series B 2008; 70:371–388.
25. Kim Y. Missing data handling in chronic pain trials. Journal of Biopharmaceutical Statistics. 2011; 21(2):311–325.
26. Kenward MG, Molenberghs G. Last observation carried forward: a crystal ball? Journal of Biopharmaceutical Statistics. 2009; 19:872–888.
27. SAS Institute Inc. SAS/STAT®;9.4. User's guide. SAS Institute Inc: Cary, NC, 2013.
28. Ayela B, Lipkovich I, Molenberghs G, Mallinckrodt CH. A multiple imputation-based approach to sensitivity analyses and effectiveness assessments in longitudinal clinical trials. Journal of Biopharmaceutical Statistics. 2014; 24(2):211–228.
29. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Journal of Clinical Psychopharmacology. 2004; 24:389–399.
30. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA. Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology. 2004; 14(6):457–470.
31. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry. 1960; 23:56–61.
32. Flemming TR. Addressing missing data in clinical trials. Annals of Internal Medicine. 2011; 154:113–117.